Enda Avoid Dexamethasone Pai

---
name: enda-avoid-dexamethasone-pai
description: Recommends against dexamethasone for glucocorticoid replacement in primary adrenal insufficiency (PAI) due to risk of Cushingoid side effects from difficult dose titration. Use when selecting a glucocorticoid for PAI management to avoid iatrogenic Cushing syndrome.
---

# Avoid Dexamethasone for PAI Treatment Due to Cushingoid Side Effects

## STEP 1 — Gather Information
Confirm diagnosis of primary adrenal insufficiency (PAI) and assess need for glucocorticoid replacement therapy.

## STEP 2 — Rule In / Rule Out
Is dexamethasone being considered for glucocorticoid replacement in PAI? If yes, proceed to avoid; if no, continue with standard glucocorticoid selection.

## STEP 3 — Classify or Stratify
Classify glucocorticoid options into preferred (hydrocortisone, cortisone acetate, prednisolone) and non-preferred (dexamethasone) for PAI based on Cushingoid risk and titration difficulty.

## STEP 4 — Decide
Select a preferred glucocorticoid (hydrocortisone 15–25 mg/day or cortisone acetate 20–35 mg/day in divided doses) and avoid dexamethasone for PAI treatment.

## Clinical Guardrails / Mimics / Pitfalls
Do not use dexamethasone for PAI due to its long half-life and lack of mineralocorticoid activity, which complicates dose titration and increases Cushingoid risk; avoid in pediatric patients; monitor for weight gain, hyperglycemia, hypertension if inadvertently used; do not rely on dexamethasone for emergency dosing.

## Concrete Clinical Example
A 50-year-old woman with confirmed PAI is being evaluated for glucocorticoid replacement; the clinician considers dexamethasone for once-daily convenience but chooses hydrocortisone 20 mg daily in two divided doses after reviewing guideline 3.4 to prevent Cushingoid complications.

**Source:** Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710